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ABSTRACT (200 words) 
This study aims to determine the course of vision loss after Baerveldt aqueous 
tube shunt placement and identify risk factors associated with unexplained severe long-
term vision loss, or snuff-out.  We retrospectively reviewed 247 eyes of 222 patients who 
underwent Baerveldt implantations at one of two academic institutions.  Postoperative 
vision loss at 6 months following surgery was categorized as mild-to-moderate versus 
severe and long-term versus transient.  Long-term vision loss, defined as 3 or more lines 
of Snellen visual acuity (VA) loss compared with preoperative VA, occurred in 63 of 247 
eyes (25.5%), and 39 had mild-to-moderate and 24 had severe loss.  Of these 63 eyes, 18 
had no identifiable cause of vision loss.  On multivariate analysis, poorer Snellen VA on 
postoperative day 1 (POD1) was found to be a significant risk factor for long-term vision 
loss (p=0.005).  In addition, the negative change in preoperative versus POD1 Snellen 
VA (p=0.021) and the presence of split fixation involving the inferonasal quadrant on 
preoperative Humphrey visual field (p=0.044) were significant risk factors for snuff-out.  
Transient vision loss occurred in 76 of 242 eyes (30.8%).  In conclusion, vision loss is 
not uncommon after Baerveldt surgery, with snuff-out occurring in 2.4% of cases in this 
study. 
   
INTRODUCTION 
 Glaucoma drainage implants have become an increasingly popular surgical option 
in cases of refractory glaucoma or failed previous trabeculectomies [1].  Their use may be 
expanding to primary surgical management in patients with complex or congenital 
glaucoma, and even in more traditional cases with a high risk of trabeculectomy failure.  
Glaucoma drainage devices have been shown to effectively lower intraocular pressure 
(IOP) to levels similar to that after trabeculectomy and can thus reduce progression of 
glaucomatous visual field loss.  However, drainage devices are not without known 
complications, including accelerated corneal endothelial damage, hypotony, tube or plate 
erosion, strabismus, and infection. 
 Von Graefe was the first to report that central vision may be compromised soon 
after surgery in chronically glaucomatous eyes with reduced visual fields [2, 3].  We 
explored this phenomenon of “snuff-out,” or long-term severe unexplained vision loss, 
after trabeculectomy and found a 2% prevalence in the study population [4].  Furthermore, 
snuff-out was significantly associated with preoperative split fixation of visual fields, 
preoperative number of quadrants with split fixation, and the occurrence of postoperative 
choroidal effusions, even after resolution. 
However, no prior studies have explored the phenomenon of snuff-out after 
aqueous tube shunt placement.  In this study, we sought to determine the prevalence of 
and risk factors associated with short and long term vision loss and recovery with special 
attention to unexplained long-term vision loss after aqueous tube shunt surgery.  Our 
study looked specifically at Baerveldt implants (Abbott Medical Optics, Abbott Park, IL), 
which are one of the two most commonly used types of glaucoma drainage devices.  
Baerveldt implants are silicone, non-valved shunts, which require placement of a 
dissolvable or removable suture around the tube or placement of the plate and tube 
separately in a two-staged procedure. 
While it has been highly debated in the literature whether snuff out truly exists 
after trabeculectomy, to our knowledge, no prior studies have explored this phenomenon 
after aqueous shunt surgery.  This is the first study to note the prevalence of decreased 
vision after tube placement, with the distinction made between transient vision loss and 
recovery versus long-term vision loss, as well as mild-moderate versus severe vision loss, 
and to identify risk factors associated with long-term, unexplained vision loss.  
MATERIALS AND METHODS 
We retrospectively reviewed all 350-mm
2
 Baerveldt implantations performed at 
the University of Southern California (USC) Eye Institute, Keck School of Medicine, Los 
Angeles, between January 1998 and May 2011, as well as the Massachusetts Eye and Ear 
Infirmary, Harvard Medical School, Boston, between November 2005 and January 2012.  
The Institutional Review Boards at USC and Harvard University approved the study 
protocol, and all study procedures were compliant with the Health Insurance Portability 
and Accountability Act and the Declaration of Helsinski for research involving human 
participants. 
Inclusion criteria were a minimum 6-month follow-up period, baseline visual 
acuity (VA) of counting fingers or better, and one of the following glaucoma diagnoses: 
primary or secondary open-angle, chronic angle-closure, pseudoexfoliation, pigmentary, 
traumatic, low-tension, juvenile, or iridocorneal endothelial syndrome.  Exclusion criteria 
were aphakia, other concurrent surgical procedures, or a diagnosis of neovascular, 
congenital, or uveitic glaucoma.  The following preoperative characteristics were noted: 
age, sex, race, lens status, diagnosis, history of prior aqueous shunt surgery, IOP, Snellen 
VA, cup-to-disc ratio, Humphrey visual field (HVF) mean deviation, presence of split 
fixation based on HVF testing, and number of quadrants with split fixation. 
We defined split fixation in the same way as our prior study on vision loss after 
trabeculectomy: a sensitivity of less than 10 dB involving any paracentral points in the 
four cardinal quadrants (superotemporal, inferotemporal, superonasal, and inferonasal) on 
24-2 HVF examination [4].  Follow-up data was obtained at postoperative intervals of 1 
day, 1 week, 1 month, 3 months, 6 months, 12 months, then yearly thereafter, making 
note of VA, IOP, postoperative procedures, and complications, including choroidal 
effusions, flat or shallow anterior chamber, and hypotony (IOP ≤5).  Follow-up duration 
was determined as the length of time from surgery to the last follow-up visit documented.  
For two-staged Baerveldt implantations, preoperative data was obtained according to the 
Stage I date and postoperative data to the Stage II date. 
Data were evaluated for documentation of postoperative vision loss, which was 
categorized as mild-to-moderate versus severe.  Mild-to-moderate vision loss was defined 
as a decrease of 3 to 5 lines in Snellen VA compared with preoperative, baseline VA.  
Severe vision loss was defined as a decrease of more than 5 lines in Snellen VA or semi-
quantitative categories of low vision (eg, counting fingers at a given distance, with 7-10 
feet, 4-6 feet, and 1-3 feet each approximating one line of Snellen VA; hand motion; light 
perception, and no light perception) compared to baseline VA.  The determination of 
mild-to-moderate versus severe vision loss was based on the lowest observed VA within 
the 6-month postoperative period. 
Vision loss was then categorized as long-term versus transient.  Postoperative 
vision loss was considered long-term if Snellen VA did not recover to within 3 lines of 
the preoperative VA by the 6-month follow-up period.  Conversely, postoperative vision 
loss was considered transient if there was a return in vision to within 3 lines of the 
preoperative VA at the 6-month follow-up interval, with note made of the number of days 
for visual recovery.  The postoperative course was reviewed in all cases of long-term 
vision loss to identify any clinical findings or occurrences that accounted for the vision 
loss.  Cases of severe, long-term vision loss without any identifiable explanation were 
further characterized as “snuff-out”. 
Statistical analysis was performed with STATA 13.1 for Windows (StataCorp, 
College Station, TX).  All descriptive statistics were reported as mean ± standard 
deviation.  Statistical significance was defined as p ≤ 0.05, unless multiple comparisons 
were conducted, in which case the Bonferroni correction was applied. 
Preoperative and postoperative variables were compared between patients with 
long-term, unexplained vision loss and all others using logistic regression analysis.  Entry 
into the initial model was determined via univariate regression based on p ≤ 0.25.  
Elimination proceeded one variable at a time, with each iteration of the model tested for 
correct specification using the Box-Tidwell test.  Nested model iterations were compared 
using the Bayesian Information Criterion (BIC) and likelihood-ratio test, and elimination 
proceeded until the BIC indicated no further improvements.  Each model was then 
evaluated for influential observations and data entry errors through inspection of Pearson 
residuals, deviance residuals, and Pregibon leverages.  Robustness of model fit was 
evaluated through difference of chi-squares and deviances.
RESULTS 
A total of 247 eyes of 222 patients were included in the study.  All eyes 
underwent Baerveldt tube shunt placement without reported intraoperative complications 
or concomitant surgical procedures.  Table 1 summarizes the patient demographic and 
preoperative data.  The average patient age was 70.1 ± 14.7 years.  Females comprised 
49.4% of patients.  The most prevalent glaucoma diagnoses were primary open angle 
(60%) followed by chronic angle closure (16%).  Seventy-seven percent of patients were 
pseudophakic.  Thirty-one patients (13%) had aqueous shunt placement in the ipsilateral 
eye previously. 
A majority of patients demonstrated evidence of advanced glaucomatous disease.  
Over 73% had a preoperative cup-to-disc ratio ≥ 0.9, and the average mean deviation on 
HVF 24-2 was -15.2 ±8.7 dB.  Fifty-one percent of all preoperative visual fields (95 of 
186 HVFs) had split fixation in at least 1 cardinal quadrant. 
Figure 1 shows the categorical occurrences of vision loss.  108 of 247 eyes 
(43.7%) maintained vision within two Snellen lines over the 6-month postoperative 
period.  76 of 247 eyes (30.8%) had transient vision loss, of which 41 eyes (53.9%) had 
mild-to-moderate vision loss (3-5 lines of Snellen VA loss from baseline) and 35 eyes 
(46.1%) had severe loss (>5 lines of Snellen VA).  The mean time to recovery for eyes 
with transient vision loss was 73.3 ±51.8 days (range 23.5 to 176). 
Long-term vision loss was observed in 63 of 247 eyes (25.5%).  Thirty-nine of 
these cases (61.9%) were mild-to-moderate, and 24 (38.1%) were severe.  Long-term 
vision loss could be explained in 45 cases (71.4%).  The most common causes were 
progression of glaucoma, cataract, and corneal edema, accounting for 9, 8, and 8 cases, 
respectively.  All other attributable causes of long-term vision loss are listed in Figure 1.  
Eighteen cases of long-term vision loss (7.3% of cases overall) had no identifiable 
explanation.  Specifically, 6 cases, or 2.4% of all study eyes, had severe, long-term, 
unexplained vision loss and were therefore considered cases of snuff-out.  Of note, none 
of the 18 eyes with unexplained long-term vision loss were from the same patient. 
Preoperative and postoperative characteristics were compared between cases of 
unexplained long-term vision loss and all other cases (Table 2).  Logistic regression 
analysis revealed that the only factor significantly associated with unexplained long-term 
vision loss overall was postoperative day 1 (POD1) Snellen VA (OR = 1.29, 95% CI 
[1.08 – 1.55], p=0.005) (Table 3).  The presence of split fixation in the inferonasal 
quadrant on preoperative HVF was nearly significant (OR = 3.28, 95% CI [0.90 – 11.93], 
p=0.072).  Factors significantly associated with snuff-out were the change in preoperative 
versus POD1 Snellen VA (OR = 1.51, 95% CI [1.06 – 2.13], p = 0.021) and the presence 
of split fixation in the inferonasal quadrant on preoperative HVF (OR = 13.70, 95% CI 
[1.08 – 17.07], p=0.044).  No other variables examined reached statistical significance in 
the final multivariate regression analysis.  
DISCUSSION 
Our findings suggest that vision decrease is a common occurrence postoperatively 
and that snuff-out, although uncommon, does occur after aqueous tube shunt implantation.  
To the best of our knowledge, no prior reports specifically explored the course of and risk 
factors associated with snuff-out after aqueous tube shunt surgery.  However, several 
studies have described visual acuity outcomes in general after Baerveldt implantation, as 
summarized in Table 4 [5-15]. 
These previous studies often sought to compare the efficacy of Baerveldt shunts 
with trabeculectomy or alternative shunt types.  They only compared VA at baseline with 
a single time point after aqueous shunt surgery, with no comments made regarding the 
course of vision loss and recovery.  Moreover, these studies had varying follow-up 
periods with notable differences in inclusion and exclusion criteria, such that a direct 
comparison of results between these studies and the present one is not possible.  
Nevertheless, these prior studies reported an overall mean reduction in logMAR Snellen 
VA ranging from 0.16 units to 1.6 units  (mean of 0.53) with a follow-up period ranging 
from one to five years after Baerveldt implantation.  When visual acuities in this study 
were converted to their logMAR equivalents, the overall mean reduction in VA was 0.16 
units ± 0.49, which is comparable to the aforementioned studies. 
A few studies specified the degree of vision loss or gain based on the change in 
Snellen VA from baseline to postoperatively.  Christakis et al looked at 114 eyes in 114 
patients who were randomly assigned to Baerveldt shunt placement, and after three years 
of follow-up, found that approximately 18% of patients lost 3-4 lines of Snellen VA and 
approximately 23% lost ≥ 5 lines Snellen VA [7, 16].  This subdivision is comparable to 
our definition of mild-to-moderate and severe vision loss, which we defined as 3-5 lines 
of Snellen VA and >5 lines of Snellen VA from baseline, respectively.  At 15.8%, our 
rate of long-term mild-to-moderate vision loss was similar to the 18% reported by 
Christakis et al.  However, our rate of severe long-term vision loss of 9.7% was 
significantly less than the 23% Christakis et al reported.  Given that our minimum 
follow-up period was six months compared with three years in the previous study, this 
discrepancy in severe vision loss may be due to patients losing vision over time from 
progression of their underlying glaucoma.  Christakis et al did not address reasons for 
vision loss in their study. 
Two other study series distinguished a loss of 2 or more Snellen lines after 
Baerveldt placement, with rates ranging from 30% to 46% over a follow-up period of one 
to five years[5, 6, 8, 9, 11, 17].  This degree of vision loss (≥2 lines Snellen VA) is nearly 
equivalent to the sum of our mild-to-moderate and severe vision loss cases, or 25.5% of 
all cases, in the current study.  Our rate of long-term vision loss may be lower than those 
previously reported since these studies included patients with a 2-line reduction in 
Snellen VA, whereas our definition of vision loss started with 3 or more Snellen lines lost.  
In addition, many prior studies included eyes with neovascular and uveitic glaucoma, 
which were excluded from the present study, given the high failure rates and overall poor 
visual outcomes.  Furthermore, endpoints of these study studies were later than our six 
months of follow-up, after which patients may suffer vision loss due to glaucomatous 
progression. 
The Tube Versus Trabeculectomy (TVT) and Ahmed Baerveldt Comparison 
(ABC) studies attempted to identify causes of vision loss[5, 6, 8, 9, 11, 17].  In the TVT 
studies, Gedde et al identified postoperative complications, specifically persistent corneal 
edema and choroidal effusions, as independent risk factors for vision loss 1 year after 
Baerveldt placement.  This was not explored in subsequent studies.  The authors cited 
progression of glaucoma, macular disease, and cataracts as the most common reasons for 
vision loss, with 7.2% of the Baerveldt cohort suffering vision loss for unknown reasons 
at five years follow-up.  This was similar to the 7.3% occurrence of unexplained long-
term vision loss in our study, with progression of glaucoma, corneal edema, cataracts, 
and hypotony maculopathy accounting for the four most common explanations of long-
term vision loss. 
In the ABC studies, Budenz et al separated patients into 4 strata: Stratum 1- 
primary glaucoma with previous surgery, Stratum 2- secondary glaucomas (excluding 
neovascular and uveitic glaucomas), Stratum 3- neovascular glaucoma, and Stratum 4- 
uveitic glaucoma[18].  At one-year follow-up, the authors found certain diagnostic strata 
(namely, neovascular glaucoma and “high-risk strata”) and better pre-operative VA to be 
highly predictive of VA loss of 2 or more Snellen lines.  This was not addressed in 
subsequent studies.  Neovascular and uveitic glaucomas were excluded in the present 
study so a direct comparison with these results is not possible.  The authors also found 
progression of glaucoma, macular disease, and cataract to be the most frequent causes of 
vision loss after Baerveldt placement, with unexplained vision loss occurring in 15% of 
patients in the overall study population.  In contrast with the findings from Gedde et al, 
postoperative complications were not statistically associated with vision loss. 
While these prior studies explored reasons for vision loss, this paper sought to 
identify and predict unexplained vision loss.  While this has not been characterized with 
respect to aqueous shunt surgery, several published studies have explored the risk of 
snuff-out after trabeculectomy [4, 19-24].  Francis et al published the most recent study 
exploring vision loss and snuff-out after trabeculectomy [4].  Among 301 eyes in 262 
patients, the authors reported a 2.0% rate of snuff-out after trabeculectomy.  While this 
focuses on a different type of glaucoma surgery, interestingly, we found a similar rate of 
snuff-out in the present study of 2.4%.  On univariate analysis, Francis et al found that 
risk factors for long-term vision loss were the presence of split fixation on preoperative 
HVF, the number of cardinal quadrants with split fixation, and postoperative choroidal 
effusions with eventual resolution.  A limitation of the prior study was the lack of 
multivariate analysis.  Our current multivariate analysis revealed that of the variables that 
Francis et al studied, only the presence of split fixation in the inferonasal quadrant was 
statistically significant for snuff-out after Baerveldt implantation. 
One speculation as to why split fixation may be a risk factor for snuff-out is the 
fact that fixation is supplied by the maculopapular fiber bundle, which is often a late 
portion of retinal nerve fiber layer to be compromised in glaucomatous optic nerve 
damage.  Therefore, the presence of split fixation may suggest that the underlying 
glaucoma is often so advanced that loss of any remaining fixation points may occur more 
easily, especially after a traumatic event such as glaucoma surgery, and thereby lead to 
snuff-out post-operatively. 
Limitations of this study include the flaws inherent in a retrospective study, 
including the non-randomization of patients and the lack of regular HVF examinations.  
The decision to perform tube shunt placement was made by the treating physician on the 
basis of overall patient status but was not strictly standardized.  Of the 247 eyes included 
in this study, only 186 eyes had undergone preoperative HVF testing.  Visual fields were 
not performed in the remaining 61 patients due to poor preoperative visual acuity (≤ 
20/200) and/or excessively high IOP necessitating urgent tube placement.  In addition, 
because snuff-out is an uncommon phenomenon, it was necessary to include both eyes 
from some patients to gain proper statistical power for this retrospective review.  
However, none of the 18 eyes with unexplained long-term vision loss were from the same 
patient.  Moreover, there was no statistically significant difference in the results when 
only one eye of these patients was randomly selected for the analysis.  Finally, there may 
have been a bias toward underestimating the incidence of snuff-out if surgeons suspected 
this possibility in patients with advanced vision loss and therefore did not operate with 
equal frequency on these patients. 
In conclusion, our findings suggest that transient vision loss is common and takes 
an average of 2.5 months to recover following Baerveldt placement.  Long-term vision 
loss occurs less commonly, but still comprises a significant proportion of patients and 
should thus be included in patient education about the risks and benefits of surgery.  
Snuff-out, or severe unexplained long-term vision loss, was an uncommon phenomenon, 
occurring in 2.4% of cases after Baerveldt implantation.  Poorer POD1 VA may herald a 
worse prognosis in the long term, and the level of visual field loss, especially the 
presence of inferonasal split fixation on preoperative HVF, may help identify patients at 
highest risk for snuff-out.  The results of this study aim to elucidate the course of vision 
loss and recovery after Baerveldt placement and to better identify risk factors for 
unexplained long-term vision loss and snuff-out.
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CONCLUSIONS 
This is the first study that seeks to explore the phenomenon of snuff-out, or 
unexplained severe long-term vision loss, after aqueous tube shunt placement.  Predictive 
risk factors for snuff-out are the degree of vision loss on POD1 and the presence of split 
fixation involving the inferonasal quadrant on preoperative visual field testing.  Long-
term vision loss is not uncommon after Baerveldt tube shunt implantation, with snuff-out 
occurring in 2.4% of cases in this study.   
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FIGURES and FIGURE LEGENDS 
 
FIGURE. Incidence of Vision Loss Among 247 Eyes in 222 Patients Six Months After 
Baerveldt Glaucoma Tube Shunt Implantation  
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TABLE 1. Baseline Preoperative Demographics of 222 Patients Undergoing Baerveldt 
Glaucoma Tube Shunt Implantation in 247 Eyes 
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TABLE 2. Descriptive Characteristics of Unexplained Long-Term Vision Loss Among 
247 Eyes After Baerveldt Tube Shunt Implantation 
† indicates variable met inclusion criteria for the model for snuff-out (severe unexplained 
permanent vision loss) 
‡ indicates variable met inclusion criteria the model for unexplained permanent vision 
loss (including mild to moderate and severe) 
Ø 
indicates variable was perfectly predictive of snuff-out 
* indicates variable was perfectly predictive of unexplained permanent vision loss  
HM= hand motion visual acuity 
LP= light perception only visual acuity 
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TABLE 3. Multivariate Analyses for Risk Factors Predicting Unexplained Long-Term 
Vision Loss 
Coefficients are presented as odd ratios. 95% Confidence Intervals for odds ratios appear 
in brackets.  
* indicates significance at the 0.05 level 
** indicates significance at the 0.01 level 
*** indicates significance at the 0.001 level  
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TABLE 4. Prior Studies of Vision Loss After Baerveldt Tube Shunt Implantation 
Abbreviations: BVI= Baerveldt implant; CACG= chronic angle closure glaucoma; 
CE/IOL= cataract extraction with intraocular lens implantation; f/u = follow-up; NLP= 
no light perception; NVG= neovascular glaucoma; OAG= open angle glaucoma; post-
op= post-operatively; PXE= pseudoexfoliation; Trab= trabeculectomy; VA= visual acuity 
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